Manipulated data in 17 papers from one cancer research lab in China gets flagged on PubPeer. It ends with the university hospital in Wuhan issuing a secret statement accusing the US pharma giant a Merck of a conspiracy to slander a Chinese Academy member, Dr Ding Ma.
The team around the paediatric oncologist Nabil Ahmed at Baylor College of Medicine in Houston, Texas, discovered a way to engineer T-leukocytes to bypass the blood-brain barrier at attack otherwise untreatable brain cancers. Their amazing technology to get this published in Nature was brazenly insolent data fakery.
Frontiers is a somewhat unconventional open access publisher, which likes to have it both ways: playing scientific elite while accepting almost anything from paying customers. My regular contributor Smut Clyde will tell you below how some anti-vaccine scare-mongers managed to sneak in some rather dangerous works thanks to Frontiers’ unofficial “we don’t judge, we just charge” quasi-policy.
First gene-edited human babies were allegedly born, two twin girls. Jiankui He, associate professor at the South University of Science and Technology of China claimed to have used CRISPR gene editing technology, in a registered clinical trial, to make babies resistant to HIV. Did this really happen? In any case, everyone now takes distance to He.
Smut Clyde will take you on a meditative Ayurvedic trip where the most respectable of research institutions and their world-renowned academics were caught dancing with the Guru Deepak Chopra himself. Famous cardiologist and medical writer Eric Topol and the Nobel Prize winner Elizabeth Blackburn were just two most prominent US academics listed on Chopra’s Panchakarma clinical trial.
The hero of this new nano-malfeasance story by Smut Clyde is another Chinese Photoshop-enthusiast, Rijun Gui, a “specially recruited professor” at Qingdao University in China. There is also a female lead, Gui’s wife and colleague Hui Jin. Almost 30 of their papers, mostly published in Elsevier journals, are being discussed on and by PubPeer, one was already retracted by the Royal Society of Chemistry.